Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

Strategic acquisitions transform Cerecor into a leading U.S. Pediatric Pharmaceutical Company

Company announces initiation of a clinical development program for CERC-301 in Neurogenic Orthostatic Hypotension

BALTIMORE, MD — (Marketwired) — 04/02/18 — Cerecor Inc. (NASDAQ: CERC) today announced financial results for the fourth quarter and full year 2017. Net Revenues for the year ended 2017 were $27.8 million. As of December 31, 2017, the Company had $43.1 million in total assets including cash and cash equivalents of $2.5 million, accounts receivable of $3.3 million, and escrowed receivable of $3.8 million. Total liabilities were $15.3 million and Total Stockholder’s equity was $27.9 million.

This entry was posted in Recent Development News: Q2 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »